Docusign Just Posted Strong Earnings--So Why Did the Stock Plunge 6% Overnight?

DocuSign reported fiscal Q3 revenue of $818.4M, up 8% year-over-year, with subscription revenue of $801.0M (+9%), operating cash flow of $290.3M and free cash flow of $262.9M, while its Intelligent Agreement Management platform surpassed 25,000 customers and ~150M opted-in agreements. Management highlighted expanding AI integrations (ChatGPT, Anthropic, Gemini, GitHub and Microsoft Copilot beta support), new APIs and product expansions, plus FedRAMP/GovRAMP authorizations and international language support. Guidance calls for Q4 revenue of $825M–$829M and full-year revenue of $3.208B–$3.212B, with subscription and billings growth in the high single digits, though FX may modestly affect comparisons; the shares fell ~6.3% after the print. Investors will likely weigh improving fundamentals and AI-driven product momentum against conservative near-term growth and market skepticism.

Analysis

Market structure: DocuSign (DOCU) is the clear near-term beneficiary — AI-native contract capabilities (Navigator: 150M agreements, 25k customers) and new integrations with ChatGPT/Anthropic/MSFT increase switching costs for enterprise CLM buyers and incrementally expand pricing power. Losers are legacy on‑prem CLM vendors and small specialist providers without large repositories or partner embeds; measured guidance (Q4 revenue $825–829M) implies supply (product delivery) is not the constraint, demand remains steady but requires demonstrated AI ROI to accelerate adoption. Cross-asset: expect higher DOCU equity implied volatility and short-term equity weakness to modestly widen credit spreads for lower-rated SaaS issuers; FX headwinds may trim reported growth in Q4 and early 2026.

Risk assessment: Tail risks include regulatory/privacy action (EU/US AI data rules), hallucination-driven liability from AI contract automation, and partner concentration (MSFT/OpenAI) — low probability but high impact on renewal rates and legal costs. Immediate (days) risk is volatility and sentiment rotation; short-term (weeks–months) risk centers on billings/FX execution vs guidance; long-term (1–3 years) upside depends on genuine enterprise adoption of Navigator+AI and successful FedRAMP/GovRAMP expansions. Hidden dependencies: “opted-in” repository limits usable training data and partner integrations create single‑point risks.

Trade implications: Tactical long exposure via defined-risk options favored over outright shares given post‑earnings IV; a 6–9 month time horizon is appropriate to let AI integrations and federal wins materialize. Pair trades: long DOCU vs short CRM (Salesforce) expresses conviction in specialized CLM edge vs broad CRM valuation multiple compression. Sector: rotate modestly from legacy SaaS into AI-native enterprise software names that show FCF conversion (>8% FCF margin) and clear partner/government credibility.

Contrarian angles: The market is underpricing cash flow improvement — DOCU reported $262.9M FCF; the 6.3% selloff appears reflexive to measured guidance, not structural deterioration. Consensus may overestimate churn risk and underweight durable repo/network effects from Navigator; counter-risk is that rapid AI feature rollout increases legal/regulatory scrutiny and could force heavier compliance capex. Historical parallel: companies that turned strong FCF + enterprise trust (FedRAMP) into durable margins often re-rate over 12–24 months if execution holds.

Key Decisions for Investors

• Establish a core long position in DOCU equal to 2.5% of portfolio via phased buys: 50% immediately, 50% if shares drop an additional 8–12% from current post‑earnings level; target 12–18 month hold, trim to take profits at +40% and cut to stop‑loss at -20%.
• If preference for defined risk, buy a 6‑month DOCU call spread: buy ATM call, sell 30% OTM call, size notional equal to 1.5% portfolio upside exposure; exit at +50% of option cost or if DOCU trades below initial purchase price by 20%.
• Implement pair trade: long DOCU 1.5% portfolio vs short CRM 1.5% portfolio (dollar neutral) to express CLM-specific outperformance; reassess after next earnings from both (90 days) and unwind if DOCU billings growth <7% y/y or CRM shows >10% subscription acceleration.
• For existing DOCU holders, sell 3‑month covered calls 10–15% OTM to monetize elevated IV, or buy 6‑9 month protective puts if position >3% portfolio and you want to limit downside to -20% while retaining upside exposure.